Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Feb
17
Today In Oncology
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
Determining the Optimal Duration of Androgen-Deprivation Therapy Added to Definitive Radiotherapy in Localized Prostate Cancer
Induction Nivolumab Before CRT in High-Risk HPV-Driven OPC
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive Breast Cancer
Nonmetastatic Breast Cancer Treatment Strategies After Denosumab Discontinuation in Patients Treated With Aromatase Inhibitors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo